Compared to bupropion-naltrexone, patients on GLP-1 agonists medication had nine times higher risk of pancreatitis (inflammation of the pancreas), four times higher risk of bowel obstruction (food is prevented from passing through the small intestine) and three times higher risk of stomach paralysis
The addition of AMPLITUDE-O data refined evidence for cardiovascular benefits, in particular showing reduction in hospital admission for heart failure, and suggested exendin-4-based compounds lower risks as well as human-based GLP-1 receptor agonists, Naveed Sattar, MD, PhD, professor of metabolic medicine at the University of Glasgow in the U.K., and colleagues wrote
Triple Hormone Targeting for Enhanced Effectiveness Retatrutide is the first drug to target GLP-1, GIP, and glucagon receptors, potentially making it more powerful than existing weight-loss medications that only target one or two of these pathways
For insights on getting the best value, see our guides on affordable tirzepatide and cheap compounded tirzepatide options
The Effect of Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide on Cardiovascular and Renal Outcomes Across Baseline Blood Pressure Categories: Analysis of the LEADER and SUSTAIN 6 Trials